Selinexor has expanded the treatment horizon in myeloma by selectively inhibiting the nuclear export receptor Exportin-1 (XPO1) and disrupting the nucleocytoplasmic flow, inducing cell cycle arrest and apoptosis in cancer cells [46]. The gene discussed is XPO1; the disease is plasma cell myeloma.